Search results for " Interleukin-2"

showing 10 items of 63 documents

Subclinical gut inflammation in ankylosing spondylitis

2015

Purpose of review Subclinical gut inflammation has been described in a significant proportion of patients with ankylosing spondylitis (AS), up to 10% of them developing it during the time of clinically overt inflammatory bowel disease. Histologic, immunologic, and intestinal microbiota alterations characterize the AS gut. Recent findings Microbial dysbiosis as well as alterations of innate immune responses have been demonstrated in the gut of AS. Furthermore, a growing body of evidence suggests that the gut of AS patients may be actively involved in the pathogenesis of AS through the production of proinflammatory cytokines, such as IL-23p19, and the differentiation of potentially pathogenic…

0301 basic medicineAnkylosing spondylitis; Gut inflammation; Innate lymphoid cells; Interleukin-17; Interleukin-23; Adaptive Immunity; Animals; Cytokines; Disease Models Animal; Dysbiosis; Gastrointestinal Microbiome; Humans; Immunity Innate; Inflammation; Inflammatory Bowel Diseases; Intestines; Macrophages; Mice; Spondylitis Ankylosing; Rheumatology; Medicine (all)MacrophageAdaptive ImmunityInterleukin-23Inflammatory bowel diseaseGastroenterologyMiceInterleukin 23InnateMedicineSubclinical infectionMedicine (all)Interleukin-17digestive oral and skin physiologyInnate lymphoid cellIntestineIntestinesCytokinesmedicine.symptomHumanAnkylosingmedicine.medical_specialtyDisease ModelInflammationdigestive system03 medical and health sciencesRheumatologyInternal medicineInnate lymphoid cellAnimalsHumansSpondylitis AnkylosingCytokineSpondylitisGut inflammationSpondylitiInflammationAnkylosing spondylitisAnimalbusiness.industryMacrophagesInflammatory Bowel DiseaseImmunityInflammatory Bowel Diseasesmedicine.diseaseImmunity InnateDysbiosiGastrointestinal MicrobiomeAnkylosing spondylitiDisease Models Animal030104 developmental biologyDysbiosisbusinessDysbiosisCurrent Opinion in Rheumatology
researchProduct

Increased expression of interleukin-22 in patients with giant cell arteritis

2017

Objectives GCA is characterized by arterial remodelling driven by inflammation. IL-22 is an attractive cytokine which acts at the crosstalk between immune and stromal cells. We hypothesized that IL-22 might be induced in GCA and might be involved in disease pathogenesis. Methods Patients subjected to temporal artery biopsies (TABs) naive from therapy were enrolled: 27 biopsy-proven GCA, 8 biopsy-negative GCA, 21 biopsy-negative non-GCA patients. Expression of IL-22 was determined in TABs by immunohystochemistry, in plasma by ELISA, in peripheral blood mononuclear cells by real-time PCR and flow cytometry. Effects of IL-22 on viability and gene expression of primary cultures obtained from TA…

0301 basic medicineCD4-Positive T-LymphocytesMalearterial remodelling; autoimmunity; giant cell arteritis; inflammation; interleukin-22; pathogenesismedicine.medical_treatmentMessengerInterleukin 220302 clinical medicineimmune system diseasesarterial remodelling; autoimmunity; giant cell arteritis; inflammation; interleukin-22; pathogenesis; Aged; Aged 80 and over; CD4-Positive T-Lymphocytes; Calcium Ionophores; Carcinogens; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Giant Cell Arteritis; Humans; Immunohistochemistry; In Vitro Techniques; Interleukins; Ionomycin; Leukocytes Mononuclear; Male; RNA Messenger; Real-Time Polymerase Chain Reaction; Temporal Arteries; Tetradecanoylphorbol Acetate80 and overLeukocytesPharmacology (medical)skin and connective tissue diseasesAged 80 and overIonomycinpathogenesisautoimmunityInterleukinFlow CytometryImmunohistochemistryTemporal ArteriesCalcium IonophoresCytokinecardiovascular systemTetradecanoylphorbol AcetateFemalemedicine.symptomgiant cell arteritiStromal cellMononuclearGiant Cell ArteritisInflammationEnzyme-Linked Immunosorbent AssayIn Vitro TechniquesReal-Time Polymerase Chain ReactionPeripheral blood mononuclear cellarterial remodelling03 medical and health sciencesRheumatologymedicineHumansViability assayRNA Messengercardiovascular diseasesAged030203 arthritis & rheumatologybusiness.industryInterleukinsinterleukin-22medicine.diseaseGiant cell arteritis030104 developmental biologyinflammationCase-Control StudiesImmunologyCarcinogensLeukocytes MononuclearRNAbusiness
researchProduct

Study of T-cell activation in Type I diabetic patients and pre-Type I diabetic subjects by cytometric analysis: Antigen expression defectin vitro

1993

In Type I diabetes the observation of a decreased release of interleukin-2 (IL-2) and soluble IL-2 receptors by means of stimulated lymphocytes in vitro indicates that a primary immunoregulatory defect may be involved. To confirm this hypothesis we investigated the T-cell activation trend, evaluating the surface expression of IL-2 receptor (CD25), transferrin (CD71), HLA class II (DR), and CD69 phenotypes after in vitro stimulation with phytohemagglutinin (PHA; 1 and 10 micrograms/ml) and concanavalin A (12.5 micrograms/ml) in six newly diagnosed Type I diabetics and six islet cell- and insulin autoantibody-positive first-degree relatives. As controls were studied six long-standing Type I d…

AdultAntigens Differentiation T-LymphocyteCD4-Positive T-LymphocytesMaleInterleukin 2medicine.medical_specialtyTime FactorsAdolescentCD3 ComplexCD8 AntigensT-Lymphocytesmedicine.medical_treatmentT cellImmunologyTransferrin receptorBiologyLymphocyte ActivationAntigenAntigens CDInternal medicineDiabetes mellitusReceptors TransferrinmedicineHumansImmunology and AllergyLectins C-TypeIL-2 receptorPhytohemagglutininsReceptorInsulinReceptors Interleukin-2HLA-DR Antigensmedicine.diseaseAntigens Differentiation B-LymphocyteKineticsDiabetes Mellitus Type 1Endocrinologymedicine.anatomical_structureInterleukin-2Femalemedicine.drugJournal of Clinical Immunology
researchProduct

Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus

1990

A clinical trial was undertaken to determine whether intensive thymopentin administration enhances remission of insulin-dependent diabetes (IDDM) during the first year after diagnosis. Dosage with insulin was minimized with target control of blood glucose levels less than or equal to 7.8 mmol/l before meals. Remission was defined as a prolonged period after IDDM onset (not less than 3 months) characterized by a non-insulin-receiving (NIR) state in which target metabolic control was reached without administration of insulin and with a valid C-peptide response, evaluated after standard breakfast. Sixteen IDDM patients aged 12-31 years, recruited within 2 weeks of initiation of insulin therapy…

AdultBlood Glucosemedicine.medical_specialtyAdolescentmedicine.medical_treatmentImmunologyGastroenterologyInternal medicineDiabetes mellitusmedicineHumansInsulinImmunology and AllergyThymopentinChildGlycemicImmunity CellularC-Peptidebusiness.industryInsulinRemission InductionHemoglobin AReceptors Interleukin-2medicine.diseaseClinical trialTiterDiabetes Mellitus Type 1EndocrinologyChild PreschoolInsulin dependent diabetesMetabolic control analysisThymopentinbusinessmedicine.drugJournal of Autoimmunity
researchProduct

Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy.

1989

Abstract The effect of recombinant human granulocyte colony-stimulating factor (G-CSF) on hematologic parameters was evaluated in a phase I clinical study in 18 patients with advanced malignancy. G-CSF was administered once daily as a 30-minute infusion for 14 days; three patients each were treated at increasing dose levels of 1, 3, 10, 30, and 60 micrograms kg-1 day-1. A transient decrease in neutrophil and monocyte counts was observed immediately after the G-CSF infusion, followed by a dose-dependent increase of up to 15-fold. G-CSF-induced neutrophils exhibited an increased O2- radical production, and serum levels of enzymes related to granulocyte turnover, including lysozyme and elastas…

AdultBlood Plateletsmedicine.medical_specialtySide effectImmunologyAntineoplastic AgentsPlatelet Membrane GlycoproteinsGranulocyteMalignancyBiochemistryLeukocyte CountColony-Stimulating FactorsSuperoxidesInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansPlateletBone painAgedbusiness.industryPlatelet CountMonocyteElastaseReceptors Interleukin-2Cell BiologyHematologyMiddle Agedmedicine.diseaseRecombinant ProteinsGranulocyte colony-stimulating factorHematopoiesisEndocrinologymedicine.anatomical_structureImmunologyDrug Evaluationmedicine.symptombusinessBlood
researchProduct

Correlation of Clinical and Immunologic Parameters of the Inflammatory Activity of Pulmonary Sarcoidosis

1991

The evaluation of activation markers such as T4/T8 ratio and HLA-DR expression of lymphocytes of bronchoalveolar lavage (L-BAL) is an important clinical approach for the staging of sarcoidosis. However, it is not known to what extent this is paralleled by an exaggerated lymphocyte function. We investigated the dependence of L-BAL activation markers on the production of interleukin-2 (IL-2) by L-BAL and on the soluble IL-2 receptor serum level (sIL-2R) in 116 patients with sarcoidosis. In none of the combinations tested was a correlation between the two groups of parameters found; r less than 0.5, upper 90% confidence limit of r less than 0.8. Interestingly, IL-2 production is independent of…

AdultLung DiseasesMalePulmonary and Respiratory MedicineSystemic diseaseSarcoidosisT-LymphocytesLymphocyteCD4-CD8 RatioCD4-CD8 RatioEnzyme-Linked Immunosorbent AssayInflammationLymphocyte ActivationHumansMedicineReceptormedicine.diagnostic_testbusiness.industryRespiratory diseaseReceptors Interleukin-2HLA-DR Antigensrespiratory systemmedicine.diseaserespiratory tract diseasesBronchoalveolar lavagemedicine.anatomical_structureImmunologyInterleukin-2FemaleSarcoidosismedicine.symptombusinessBronchoalveolar Lavage FluidAmerican Review of Respiratory Disease
researchProduct

Interleukin 2 and soluble interleukin 2-receptor secretion defect in vitro in newly diagnosed type I diabetic patients

1989

In this study, we investigated whether an interleukin 2 (IL-2) secretion defect by peripheral blood mononuclear cells (PBMCs) after in vitro stimulation with phytohemagglutinin (PHA-M) occurs in either newly diagnosed or long-standing type I (insulin-dependent) diabetic patients and whether it is accompanied by a dysregulation of soluble IL-2— receptor (IL-2RS) production. PBMC cultures (2.5 × 106 cells), unstimulated or stimulated with PHA-M (25 μg/ml), from 20 type I diabetic patients (10 with time since onset <3 mo and 10 with long-term diabetes of <3 yr) and 10 control subjects were studied for the production of IL-2 and IL-2RS in their respective supernatants. No differen…

AdultMaleInterleukin 2medicine.medical_specialtyTime FactorsAdolescentEndocrinology Diabetes and MetabolismStimulationPeripheral blood mononuclear cellIn vivoInternal medicineInternal MedicinemedicineHumansSecretionPhytohemagglutininsChildReceptorCells Culturedbusiness.industryLymphokineReceptors Interleukin-2In vitroDiabetes Mellitus Type 1EndocrinologySolubilityLeukocytes MononuclearInterleukin-2Femalebusinessmedicine.drug
researchProduct

LOW-DOSE INTERLEUKIN-2 INDUCES SYSTEMIC IMMUNE RESPONSES AGAINST HBsAg IN IMMUNODEFICIENT NON-RESPONDERS TO HEPATITIS B VACCINATION

1989

Abstract A metabolic monocyte defect appears to correlate with non-responsiveness to hepatitis B vaccine in many patients on haemodialysis. This defect prevents production of interleukin-2 during T-cell activation after antigen contact. Receptors for interleukin-2 are, however, expressed in greater numbers than in healthy subjects or uraemic responders to hepatitis B vaccination. In this study, ten uraemic patients, previous non-responders to vaccination against hepatitis B, were revaccinated with the same vaccine combined with one intramuscular injection (2·5 × 10 5 U) of natural human interleukin-2. Systemic production of antibodies against hepatitis B surface antigen was initiated in tho…

AdultMaleViral Hepatitis VaccinesInterleukin 2HBsAgHepatitis B vaccinePilot ProjectsImmunoenzyme TechniquesImmune systemAntigenmedicineHumansHepatitis B VaccinesAgedUremiaHepatitis B Surface Antigensbiologybusiness.industryImmunologic Deficiency SyndromesReceptors Interleukin-2General MedicineMiddle AgedHepatitis Bmedicine.diseaseVirologyVaccinationAntibody FormationImmunologybiology.proteinInterleukin-2FemaleAntibodybusinessmedicine.drugThe Lancet
researchProduct

Prevalence of blood-borne viral infections (cytomegalovirus, human herpesvirus-6, human herpesvirus-7, human herpesvirus-8, human T-cell lymphotropic…

2002

The identification of blood-borne viral infections is important in transfusion medicine. The aim of this study was to evaluate the prevalence of human herpesvirus (HHV) [cytomegalovirus (CMV), HHV-6, HHV-7 HHV-8] and human retrovirus (HRV) (human T-cell lymphotropic virus (HTLV)-I/II, HRV-5) infections among apparently healthy Latvian blood donors. DNA extracted from peripheral blood leukocytes (PBL) of 150 individuals was tested for herpesviruses by sensitive polymerase chain reaction (PCR) technique. None of the blood donors was positive for HHV-8 infection, while the incidence of latent beta-herpesvirus infections was high: single infection by CMV, HHV-6, and HHV-7 was detected in 2.6%, …

AdultMalemedicine.medical_specialtyAdolescentHerpesvirus 6 HumanvirusesRoseolovirus InfectionsBlood DonorsHerpesvirus 7 HumanBiologymedicine.disease_causeHerpesviridaeVirusInternal medicinemedicineHumansAgedHematologyvirus diseasesReceptors Interleukin-2CytomegalovirusHerpesviridae InfectionsHematologyGeneral MedicineMiddle AgedProvirusbiology.organism_classificationHTLV-I InfectionsLatviaVirologyBloodCytomegalovirus InfectionsDNA ViralHTLV-II InfectionsHerpesvirus 8 HumanImmunologyHTLV-II InfectionsFemaleHuman herpesvirus 6Viral diseaseBiomarkersRetroviridae InfectionsAnnals of Hematology
researchProduct

The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients

1990

In autoimmune disease the functional deficiency of T suppressor cells, also described in Type I diabetes, may be restored through immunoglobulin (Ig) infusion, which increases antigen phagocytosis, NK activity, cell clones and antibody anti-idiotype responses. Sixteen Type I diabetic patients were studied: eight were treated soon after the initial correction of disease-onset glycemic deterioration with intensive intravenous (i.v.) 7S Ig treatment (0.4 g/kg/BW) for 1 week and once per week for 6 months, whilst the remaining patients constituted the control group. All patients were evaluated during the study for metabolic and immunological parameters. A reduction in insulin requirement compar…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentPhagocytosisImmunologyCellAutoimmune DiseasesRandom AllocationAntigenInternal medicinemedicineHumansInsulinImmunology and AllergyChildAutoantibodiesGlycemicAutoimmune diseaseC-Peptidebiologybusiness.industryInsulinImmunization PassiveReceptors Interleukin-2medicine.diseaseDiabetes Mellitus Type 1medicine.anatomical_structureEndocrinologyIntravenous ImmunoglobulinsChild Preschoolbiology.proteinFemaleAntibodybusinessJournal of Autoimmunity
researchProduct